Optimizing Abemaciclib Tolerability and Dose Escalation

Strategies to improve tolerability and adherence to abemaciclib in the adjuvant setting are examined in detail. The discussion focuses on early discontinuation driven by gastrointestinal toxicity and how dose escalation approaches can reduce treatment drop-off. Evidence showing that dose reductions do not compromise efficacy is reviewed, reinforcing the value of proactive toxicity management. The faculty also address practical challenges such as pharmacy logistics, insurance approvals, and patient education. These insights help clinicians support patients through the early months of therapy and maximize the likelihood of completing treatment.